Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (37.2), the stock would be worth ¥66.89 (21% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 30.7 | ¥55.06 |
0%
|
| 3-Year Average | 37.2 | ¥66.89 |
+21%
|
| 5-Year Average | 31 | ¥55.74 |
+1%
|
| Industry Average | 28.7 | ¥51.62 |
-6%
|
| Country Average | 28.8 | ¥51.73 |
-6%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
|
3.7B CNY | 30.7 | 36 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 62.8 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 21.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 30.7 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 22.8 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 25.9 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 33.6 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 20.9 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 43.2 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 22.3 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 16.9 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Medprin Regenerative Medical Technologies Co Ltd
Glance View
Medprin Regenerative Medical Technologies Co. Ltd. engages in the development of implanted medical devices. The company is headquartered in Guangzhou, Guangdong and currently employs 271 full-time employees. The company went IPO on 2021-07-26. The firm's implanted medical device products include artificial dura mater (spine) patch, cranio-maxillofacial repair products and absorbable hemostatic yarns. 3D printing equipment includes biological 3D printers, resin 3D printers and other related supporting components. Technical services include general technical services and scientific research services. The firm distributes its products both in the domestic market and to overseas markets.
